Summary

Expands Medicare to cover at‑home treatment for Alpha‑1 Antitrypsin Deficiency when augmentation therapy is given by qualified home infusion therapy suppliers. It spells out who is eligible, what the therapy includes, and which providers can deliver it. Medicare must pay for intravenous administration kits and up to 2 hours of nursing services tied to the therapy. It updates related Medicare payment and home health rules so the benefit works smoothly. The changes apply to items and services furnished on or after January 1, 2027.

Key Points

• Adds Medicare coverage for at‑home AATD augmentation therapy.
• Coverage is limited to therapy delivered by qualified home infusion therapy suppliers.
• Medicare will pay for IV administration kits tied to the therapy.
• Medicare will pay for up to 2 hours of nursing services per treatment visit.
• Defines eligible patients, covered therapy, and qualified providers/suppliers.
• Updates related Medicare and home health rules for consistent billing and coverage.
• Effective for services furnished on or after January 1, 2027.
• Improves access and convenience for patients who can receive safe, supervised infusions at home.

Categories & Tags